Know Cancer

or
forgot password

Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development


N/A
4 Years
N/A
Not Enrolling
Both
Alveolar Soft Part Sarcoma, Sarcoma

Thank you

Trial Information

Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development


Background:

Alveolar soft part sarcoma (ASPS) is a rare tumor.

ASPS is resistant to chemotherapy and radiation.

ASPS is characterized by slow growth.

Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic
studies or biological investigations were generated under this protocol.

Additional models are needed to represent the heterogeneity of this disease.

Primary Objectives:

Acquisition of blood and tissue from patients with ASPS.

Acquisition of blood from healthy controls for comparison with blood from patients with
ASPS. These control samples will be obtained from study NCI at Frederick Protocol
OH99-C-N046.

Eligibility:

Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma who
are undergoing medically indicated surgery for their disease.

Design:

Patients with Alveolar Soft Part Sarcoma (ASPS) will be eligible for this study. Biopsy
tissue will be obtained as an additional sample at the time of a medically indicated
procedure. Blood sample may be collected at initial visit and follow-up visits. Specific
risks will be described in a separate consent to be obtained at the time of the biopsy.
Tumor samples and blood samples will be processed and/or stored for use in research efforts
in the laboratory of Dr. Robert Shoemaker, National Cancer Institute, Frederick, MD.
Additionally, blood samples will be obtained from healthy volunteers for comparison to
patients with ASPS. These control samples will be obtained from the National Cancer
Institute at Frederick Protocol OH99-C-N046.

Inclusion Criteria


- INCLUSION CRITERIA:

Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma
who are undergoing medically indicated surgery for their disease.

EXCLUSION CRITERIA:

None.

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Michael Dean, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

999905138

NCT ID:

NCT00340353

Start Date:

April 2005

Completion Date:

April 2012

Related Keywords:

  • Alveolar Soft Part Sarcoma
  • Sarcoma
  • Gene Expression
  • Drug Sensitivity
  • TFE3
  • ASPL-TFE3
  • NOD-SCID Mice
  • Sarcoma
  • Alveolar Soft Part Sarcoma
  • ASPS
  • Sarcoma, Alveolar Soft Part
  • Sarcoma

Name

Location

National Cancer Institute (NCI), 9000 Rockville PikeBethesda, Maryland  20892